{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-001175","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.925170+00:00","generated_at":"2026-05-17T15:35:48.380113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep","bullets":["Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.","Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.","Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.","Cash and restricted cash $253.4M, extended runway into 2028.","ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-001175","json":"https://secwatch.observer/filing/0001193805-25-001175.json","markdown":"https://secwatch.observer/filing/0001193805-25-001175.md","text":"https://secwatch.observer/filing/0001193805-25-001175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/0001193805-25-001175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/e664773_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:35:48.380113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}